Title : Proteolytic degradation of MAD3 (I kappa B alpha) and enhanced processing of the NF-kappa B precursor p105 are obligatory steps in the activation of NF-kappa B.

Pub. Date : 1993 Nov 11

PMID : 8255759






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Treatment of cells with tumour necrosis factor (TNF), double-stranded RNA (dsRNA), or phorbol esters is shown to be associated with an increase in the rate of p105 to p50 processing, and the loss of immunologically detectable MAD3/I kappa B alpha. Phorbol Esters NFKB inhibitor alpha Homo sapiens
2 Treatment of cells with tumour necrosis factor (TNF), double-stranded RNA (dsRNA), or phorbol esters is shown to be associated with an increase in the rate of p105 to p50 processing, and the loss of immunologically detectable MAD3/I kappa B alpha. Phorbol Esters NFKB inhibitor alpha Homo sapiens
3 Phosphate-labelling experiments indicate that these events are preceded by the phosphorylation of MAD3 and p105. Phosphates NFKB inhibitor alpha Homo sapiens
4 The protease inhibitors TLCK (N alpha-p-Tosyl-L-Lysine Chloromethyl Ketone) and TPCK (N alpha-p-Tosyl-L-Phenylalanine Chloromethyl Ketone) inhibit both p105 to p50 processing and MAD3 degradation, and also cause a complete block to NF-kappa B activation. n alpha-p-tosyl-l-lysine chloromethyl ketone NFKB inhibitor alpha Homo sapiens
5 The protease inhibitors TLCK (N alpha-p-Tosyl-L-Lysine Chloromethyl Ketone) and TPCK (N alpha-p-Tosyl-L-Phenylalanine Chloromethyl Ketone) inhibit both p105 to p50 processing and MAD3 degradation, and also cause a complete block to NF-kappa B activation. n alpha-p-tosyl-l-phenylalanine chloromethyl ketone NFKB inhibitor alpha Homo sapiens